Sacubitril/valsartan

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Heart failure, NYHA class II or III

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Call for patient/clinician input open:

August 4, 2015

Brand Name:

Entresto

Project Line:

Reimbursement Review

Project Number:

SR0447-000

Call for patient/clinician input closed:

September 23, 2015

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Heart failure, NYHA class II or III

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

March 18, 2016

Request for Resubmission: Eligible (Decision Date: January 6, 2020)

Last Updated : August 4, 2015